These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37355363)

  • 41. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
    Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
    Sasaki K; Takahashi S; Ouchi K; Otsuki Y; Wakayama S; Ishioka C
    Sci Rep; 2023 Mar; 13(1):4868. PubMed ID: 36964217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
    Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
    BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
    Kim JY; Jung J; Kim KM; Lee J; Im YH
    Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
    Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
    Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Zhao L; Qu X; Wu Z; Li Y; Zhang X; Guo W
    Aging (Albany NY); 2020 Jul; 12(14):14556-14568. PubMed ID: 32694238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors.
    Sakai E; Fukuyo M; Matsusaka K; Ohata K; Doi N; Takane K; Matsuhashi N; Fukushima J; Nakajima A; Kaneda A
    Cancer Sci; 2016 Jun; 107(6):820-7. PubMed ID: 26991699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
    Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.
    Wang Z; Burigotto M; Ghetti S; Vaillant F; Tan T; Capaldo BD; Palmieri M; Hirokawa Y; Tai L; Simpson DS; Chang C; Huang AS; Lieschke E; Diepstraten ST; Kaloni D; Riffkin C; Huang DCS; Li Wai Suen CSN; Garnham AL; Gibbs P; Visvader JE; Sieber OM; Herold MJ; Fava LL; Kelly GL; Strasser A
    Cancer Discov; 2024 Feb; 14(2):362-379. PubMed ID: 37877779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Expressions of CUL4A and TP53 in Colorectal Cancer Predict Poor Survival.
    Li C; Bu J; Liao Y; Zhang J; Han J; Zhang H; Xing H; Li Z; Wu H; Liang L; Wang M; Qin W; Yang T
    Cell Physiol Biochem; 2018; 51(6):2829-2842. PubMed ID: 30562757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
    Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
    Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.